Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recurrent activating mutations of PPARγ associated with luminal bladder tumors
Natacha Rochel, Clémentine Krucker, Laure Coutos-Thévenot, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Miguel Hernández-Quiles, Marjoleine F. Broekema, Eric Kalkhoven
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 273
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
Tracy L. Rose, William H. Weir, Gregory M. Mayhew, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 9, pp. 1251-1260
Open Access | Times Cited: 127
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Ruiwen Ruan, Li Li, Xuan Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 52
Pparg signaling controls bladder cancer subtype and immune exclusion
Tiffany Tate, Tina Xiang, Sarah E. Wobker, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 56
Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells
Chang Liu, Tiffany Tate, Ekatherina Batourina, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 72
Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool
Nara Lins Meira Quintão, José Roberto Santin, Luis Carlos Stoeberl, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 68
Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer
Mingjun Shi, Xiangyu Meng, Jacqueline Fontugne, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 52
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight
Carolyn D. Hurst, Guo Cheng, Fiona M. Platt, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 12, pp. 100472-100472
Open Access | Times Cited: 41
Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling
Sha Liu, Jiazhong Shi, Liwei Wang, et al.
Free Radical Biology and Medicine (2022) Vol. 189, pp. 42-57
Open Access | Times Cited: 38
Nuclear receptors in podocyte biology and glomerular disease
Shipra Agrawal, John Cijiang He, Pierre‐Louis Tharaux
Nature Reviews Nephrology (2020) Vol. 17, Iss. 3, pp. 185-204
Closed Access | Times Cited: 47
Pushing the limits of native MS: Online SEC-native MS for structural biology applications
Evolène Deslignière, Marie Ley, Maxime Bourguet, et al.
International Journal of Mass Spectrometry (2020) Vol. 461, pp. 116502-116502
Open Access | Times Cited: 39
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program
Jovanka Gencel‐Augusto, Xiaoping Su, Yuan Qi, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1230-1249
Open Access | Times Cited: 12
Potential molecular biomarkers for the diagnosis and prognosis of bladder cancer
Junping Fan, Bo Chen, Xingqiang Lü, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116312-116312
Open Access | Times Cited: 4
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer
Sakina A. Plumber, Tiffany Tate, Hikmat Al‐Ahmadie, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Epithelial and mesenchymal compartments of the developing bladder and urethra display spatially distinct gene expression patterns
Neelam Singh, Divyeksha H Baraiya, T. Kavya, et al.
Developmental Biology (2025)
Open Access
Exploring the Interplay of Vitamin A, Retinoids and the Microbiota-Immune System Axis in Urinary Bladder Cancer Prevention and Treatment
Larisa Tratnjek, A Janev, Tadeja Kuret, et al.
IntechOpen eBooks (2025)
Closed Access
<p>High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer</p>
Mingjun Shi, Xiangyu Meng, Qiuji Wu, et al.
Cancer Management and Research (2019) Vol. Volume 11, pp. 2987-2995
Open Access | Times Cited: 30
Machine Learning-Based Detection of Bladder Cancer by Urine cfDNA Fragmentation Hotspots that Capture Cancer-Associated Molecular Features
Xiangyu Meng, Xionghui Zhou, Shuo Li, et al.
Clinical Chemistry (2024)
Closed Access | Times Cited: 3
Inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway
Xiuxiu Jiao, Sheyu Lin, Shi Xiang Benedict Lian, et al.
Neoplasma (2020) Vol. 67, Iss. 04, pp. 834-842
Open Access | Times Cited: 22
The role and function of PPARγ in bladder cancer
Tianchen Peng, Gang Wang, Songtao Cheng, et al.
Journal of Cancer (2020) Vol. 11, Iss. 13, pp. 3965-3975
Open Access | Times Cited: 21
Development, regeneration and tumorigenesis of the urothelium
Gregory Wiessner, Sakina A. Plumber, Tina Xiang, et al.
Development (2022) Vol. 149, Iss. 9
Open Access | Times Cited: 13
The urothelial gene regulatory network: understanding biology to improve bladder cancer management
Maria Ramal, Sonia Corral, Mark Kalisz, et al.
Oncogene (2023) Vol. 43, Iss. 1, pp. 1-21
Closed Access | Times Cited: 7
Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists
Sean Irwin, Craig Karr, Craig Furman, et al.
Journal of Biological Chemistry (2022) Vol. 298, Iss. 11, pp. 102539-102539
Open Access | Times Cited: 12
Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy
Mathijs Scholtes, Florus C. de Jong, Tahlita C.M. Zuiverloon, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 288-288
Open Access | Times Cited: 15
Clinical and functional heterogeneity associated with the disruption of retinoic acid receptor beta
Véronique Caron, Nicolas Chassaing, Nicola Ragge, et al.
Genetics in Medicine (2023) Vol. 25, Iss. 8, pp. 100856-100856
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top